Sangeetha Reddy (@smreddymd) profile picture

Immuno-oncologist, physician scientist, dendritic cell enthusiast, breast medical oncologist, translational researcher

UT Southwestern Medical Center
Joined August 2017
Photo by Sangeetha Reddy (@smreddymd)Photo by Sangeetha Reddy (@smreddymd)Photo by Sangeetha Reddy (@smreddymd)Photo by Sangeetha Reddy (@smreddymd)Photo by Sangeetha Reddy (@smreddymd)Photo by Sangeetha Reddy (@smreddymd)Photo by Sangeetha Reddy (@smreddymd)Photo by Sangeetha Reddy (@smreddymd)Photo by Sangeetha Reddy (@smreddymd)Photo by Sangeetha Reddy (@smreddymd)
Sangeetha Reddy retweeted
#AACR25, capturing the last night at AACR grantee award reception along with ⁦@utswcancer⁩ colleague ⁦@smreddymd⁩ ! Managed to take a photo with the one and only ⁦@AACR_CEO⁩ !Thanks the grant support from ⁦@AACR⁩ ⁦@kidneycan⁩
1
6
1
66
4,671
Sangeetha Reddy retweeted
Big congratulations @smreddymd @utswcancer !!
We congratulate Sangeetha Reddy, MD, recipient of a 2024 Victoria’s Secret Global Fund for Women’s Cancers Career Development Award, in Partnership with Pelotonia & AACR. Dr. Reddy will study the impact of CD40 agonists on the myeloid CD8 T cell axis. @VictoriasSecret @Pelotonia
1
2
11
1,049
#SABCS23 | Poster PO2-27-12 | Genomic determinants of benefit to nivolumab + low dose ipilimumab among patients with hypermutated HER2- #MBC: Results of #NIMBUS trial. #MetastaticBreastCancer @DrRBarroso @stolaney1 @nlinmd @nabihahtayob @emittendorfmd @RMJesel @smreddymd
1
5
10
1,557
After my wonderful experience at @MDAndersonNews, I've realized there is a robust academic life beyond it. Certainly, those who remain at or return to MDA also enjoy fulfilling careers. I've learned that various cancer centers contribute uniquely to breast cancer research. #SABCS23 – at San Antonio, TX
3
3
2,448
Tumor Agnostic Approaches to Care: @VivekSubbiah, Joshua Z. Drago, @DrMiaLevy, and Marleen Kok addressed this topic in a Clinical Workshop moderated by Sangeetha M. Reddy this afternoon at #SABCS23. @lab_kok @smreddymd @AACR @UTHealthSAMDA @OncoAlert
1
17
2
49
12,650
Sangeetha Reddy retweeted
The cancer #immunity cycle provides a framework to understand the series of events that generate anti-cancer immune responses. Check out this revised review that helps better understand the successes & failures of cancer #immunotherapy doi.org/10.1016/j.immuni.202…
16
1
51
6,973
Sangeetha Reddy retweeted
It is not uncommon for clinician scientists to be questioned whether they’re ‘real doctors’ or ‘true scientists’ Both The secret to a long life as a clinician scientist is the same as a long marriage. Selective deafness Great paper @ESMO_Open @DrJonLim esmoopen.com/article/S2059-7…
5
46
2
150
20,190
Highlighting the important role the innate immune system plays in immunotherapy, @smreddymd delivers an excellent lecture describing the rationale for augmenting CDK4/6i and ICB with dendritic cell therapy. #DAVAHawaiiBreast jitc.bmj.com/content/11/5/e0…
Starting Now: Immunotherapy in Breast Cancer - (Vaccine Strategies). Moderated by: Vered Stearns #DAVAHawaiiBreast
2
1
3
1,506
Sangeetha Reddy retweeted
Replying to @CarlosArteagaMD
Carlos: Thank you so much for the opportunity!
2
1
5
584
Incredible presentation at #SABCS2022 on InteractPrint by Student Doctor Lily Xu from @ithinkichan Lab! Stellar mentorship by Dr. Chan to feature this rising star at a general session! Grateful for this incredible collaboration @smreddymd @utswcancer and excited for more to come!
2
12
Sangeetha Reddy retweeted
PD1-blockade back in the game for ER+ breast cancer! 🎊Congrats to PACE trialists. 👏👏Impressive OS for pts treated with avelumab, most important no special tox in contrast to Cm7A8 and abema/pembro. aPD1 vs aPDL1? #sabcs22. #bcsm @SABCSSanAntonio
2
9
1
67
You don’t want to miss these sessions today! @smreddymd moderating “Modifying Tumor Response: Microbiome, Diet, and Fasting” from 1-2pm and @AriellaHanker presenting “Demystifying CDKs in Breast Cancer: Beyond CDK4/6” from 2-3pm at #SABCS22. @SABCSSanAntonio
1
4
1
12
Sorry the pun 🥸🤡, but for me this was RIGHTly the most interesting data from the 1st day of #SABCS22. Visceral crisis is a dramatic situation where chemo has always been the choice, but which ribo plus letrozole has shown to be more effective with less AEs @OncoAlert #bcsm
2
13
60
Sangeetha Reddy retweeted
TALENT presented by @dradityabardia Preop T-DXd +/- AI for ER+ HER2-low BC (6-8 cycles) N=58 Response by imaging with T-DXd=68%, T-DXd+AI: 58% 1 pt with pCR, 5 with RCB1 16 pts still haven't had surgery @OncoAlert #bcsm #SABCS22
2
14
31
Sangeetha Reddy retweeted
#SABCS22 Ian Krop presents the continued remarkable efficacy of TDXd in the later line HER2+ setting. 2deaths (0.5%) from ILD with total rate 10.4%. Best to use in 2nd line for optimal efficacy but it works well late! @OncoAlert
Sara Hurvitz presents #DB03 update. ▪️CBR approaching 90% for TDXd, ORR >75% ▪️Discontinuations 21% TDXd vs. 10% TDM1, ILD 15.2% (no G4/5 events) ▪️PFS 6.8 mo vs. 28.8 months ▪️Reduced risk of death by 36% #SABCS22 @OncoAlert
4
15
My fantastic colleague @smreddymd leading a full spotlight poster session on cutting edge immunotherapy! #sabcs @utswcancer
8
29
Sangeetha Reddy retweeted
monarchE: Adj ET +/- abemaciclib x 2 yrs Updated 4-year analysis iDFS HR 0.664 OS HR 0.929 Benefits seen irrespective of Ki67 Important to see benefits of abemaciclib persist beyond the completion of tx @OncoAlert #bscm #SABCS22 @professorSteph7
1
16
2
64
Sangeetha Reddy retweeted
BCI in SOFT: BCI risk was prognostic; BCI H/I was predictive of OFS benefit (low group has benefit, high group did not). More work needed to understand the biological explanation for this finding. @OncoAlert #SABCS2022 #bcsm
1
17
34
Sangeetha Reddy retweeted
More from TailoRx #SABCS2022 benefit still seek in the higher score (21-25) premenopausal population but impossible to rule out impact of menopause. @OncoAlert
7
1
23